

2. Soares A, Maia MC, Vidigal F, Marques Monteiro FS. Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice. *Oncology*. 2020; 98(1): 1–9. doi:10.1159/000502778.
3. Howlader N, Noone AM, Krapcho M (eds). SEER Cancer Statistics Review (CSR) 1975–2018. [online]. Bethesda, MD [vid. 6. 1. 2022]. Dostupné z: https://seer.cancer.gov/csr/1975_2018/.
4. Middleton RG. Surgery for Metastatic Renal Cell Carcinoma. *J Urol*. 1967; 97(6): 973–977. doi:10.1016/S0022-5347(17)63157-4.
5. Šámal V, Richter I, Paldus V, Jirásek T, Mečl J. Radiologická regrese metastatického renálního karcinomu po biologické léčbě sunitinibem - kazuistika a přehled literatury. *Ces Urol*. 2019; 23(4): 341–346.
6. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma. *J Clin Oncol*. 1999; 17(8): 2530–2530. doi:10.1200/JCO.1999. 17. 8.2530
7. Heng DY, Xie W, Regan MM, et al. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. *J Clin Oncol*. 2009; 27(34): 5794–5799. doi:10.1200/JCO.2008. 21. 4809.
8. Sobotka R, Tomáš H, Zemanová M. Zásadní význam chirurgické léčby u karcinomu ledvin, možnosti biologické léčby. *Čas Lék čes*. 2011; 150: 156–160.
9. Finke JH, Rayman PA, Ko JS, Bradley JM, Gendler SJ, Cohen PA. Modification of the Tumor Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics. *Cancer J*. 2013; 19(4): 353–364. doi:10.1097/PPO.0b013e31829da0ae.
10. Lahn M, Fisch P, Koumlihlér G, et al. Pro-Inflammatory and T Cell Inhibitory Cytokines Are Secreted at High Levels in Tumor Cell Cultures of Human Renal Cell Carcinoma. *Eur Urol*. 1999; 35(1): 70–80. doi:10.1159/000019821.
11. Bellardita L, Rancati T, Alvisi MF, et al. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. *Eur Urol*. 2013; 64(1): 30–36. doi:10.1016/j.eururo.2013. 01. 009.
12. Gatenby RA, Gawlinski ET, Tangen CM, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. *Cancer Res*. 2002; 62(18): 5218–5222.
13. de Riese W, Goldenberg K, Allhoff E, et al. Metastatic renal cell carcinoma (RCC): Spontaneous regression, long-term survival and late recurrence. *Int Urol Nephrol*. 1991; 23(1): 13–25. doi:10.1007/BF02549723.
14. Študentová H. Algoritmus léčby metastatického renálního karcinomu ledviny. *Urol. praxi*. 2011; 12(3): 152–157.
15. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy Followed by Interferon Alfa-2 b Compared with Interferon Alfa-2 b Alone for Metastatic Renal-Cell Cancer. *N Engl J Med*. 2001; 345(23): 1655–1659. doi:10.1056/NEJMoa003013.
16. Mickisch G, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. *Lancet*. 2001; 358(9286): 966–970. doi:10.1016/S0140-6736(01)06103-7.
17. Larcher A, Wallis CJD, Bex A, et al. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? *Eur Urol Oncol*. 2019; 2(4): 365–378. doi:10.1016/j.euo.2019. 04. 007.
18. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. *N Engl J Med*. 2018; 379(5): 417–427. doi:10.1056/NEJMoa1803675.
19. Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib. *JAMA Oncol*. 2019; 5(2): 164. doi:10.1001/jamaoncol.2018.5543.